As filed with the Securities and Exchange Commission on December 27, 1996.
Registration No. 333- _________________
===========================================================================
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
____________________
FORM S-3
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
____________________
BIOJECT MEDICAL TECHNOLOGIES INC.
(Exact Name of Registrant as Specified in Its Charter)
7620 SW Bridgeport Road
Portland, Oregon 97224
(503) 639-7221
(Address, including zip code, and telephone number, including area code,
of registrant's principal executive offices)
Oregon 3845 93-1099680
- ---------------------------- -------------------------- ---------------
(State or other jurisdiction (Primary Standard Industrial (I.R.S. Employer
incorporation or organization) Classification Code Number) Identification
Number)
James C. O'Shea
Chief Executive Officer
Bioject Medical Technologies Inc.
7620 SW Bridgeport Road
Portland, Oregon 97224
(503) 639-7221
(Name, address, including zip code, and telephone number, including
area code, of agent for service)
____________________
Copies to:
Christopher J. Barry, Esq.
BOGLE & GATES P.L.L.C.
Two Union Square, 601 Union Street
Seattle, Washington 98101
206-682-5151
____________________
Approximate date of commencement of proposed sale to the public: At such time
or from time to time after the effective date of this Registration Statement
as the respective Selling Shareholders shall determine.
If the only securities being registered on this Form are being offered
pursuant to dividend or interest reinvestment plans, please check the
following box. / /
If any of the securities being registered on this Form are to be offered on a
delayed or continuous basis pursuant to Rule 415 under the Securities Act of
1933, other than securities offered only in connection with dividend or
interest reinvestment plans, please check the following box. /X/
If this Form is filed to register additional securities for an offering
pursuant to Rule 462(b) under the Securities Act, please check the following
box and list the Securities Act registration statement number of the earlier
effective registration statement for the same offering. / /_________________
If this Form is a post-effective amendment filed pursuant to Rule 462(c) under
the Securities Act, check the following box and list the Securities Act
registration statement number of the earlier effective registration statement
for the same offering. / / ___________________
If the delivery of the prospectus is expected to be made pursuant to Rule 434,
please check the following box. / /
____________________
CALCULATION OF REGISTRATION FEE
<TABLE>
<CAPTION>
Proposed Maximum Proposed Maximum
Title of Shares Amount to be Offering Aggregate Offering Amount of
to be Registered Registered(1) Price Per Share(2) Price(2) Registration Fee
- ---------------- ------------- ------------------ ------------------ ----------------
<S> <C> <C> <C> <C>
COMMON STOCK 6,396,000 $0.796875 $5,096,813 $1,545.00
================ ============= ================== ================== ================
(1) Includes an indeterminate number of shares of Common Stock that may be issued in connection
with a stock split, stock dividend, recapitalization or similar event.
(2) Estimated solely for purposes of calculating the registration fee pursuant to Rule 457(c)
and based on the average of the bid and asked price of the Common Stock of the Registrant
reported on the NASDAQ National Market on December 23, 1996.
</TABLE>
____________________
The Registrant hereby amends this Registration Statement on such date or dates
as may be necessary to delay its effective date until the Registrant shall
file a further amendment which specifically states that this Registration
Statement shall thereafter become effective in accordance with Section 8(a) of
the Securities Act of 1933, as amended, or until this Registration Statement
shall become effective on such date as the Commission, acting pursuant to said
Section 8(a), may determine.
<PAGE>
- -----------------------------------------------------------------------------
Disclaimer: Information contained herein is subject to completion or
amendment. A registration statement relating to these securities has been
filed with the Securities and Exchange Commission. These securities may not be
sold nor may offers to buy be accepted prior to the time the registration
statement becomes effective. This prospectus shall not constitute an offer to
sell or the solicitation of an offer to buy nor shall there be any sale of
these securities in any State in which such offer, solicitation or sale would
be unlawful prior to registration or qualification under the securities laws
of any such State.
- -----------------------------------------------------------------------------
SUBJECT TO COMPLETION, DATED DECEMBER 27, 1996
PROSPECTUS
6,396,000 SHARES
BIOJECT MEDICAL TECHNOLOGIES INC.
COMMON STOCK
_____________________
This Prospectus pertains to the offer and sale from time to time of up to
6,396,000 shares (the "Shares") of common stock, without par value (the
"Common Stock"), of Bioject Medical Technologies Inc. ("Bioject" or the
"Company") by or for the account of certain of the Company's shareholders
(collectively, the "Selling Shareholders"). See "Selling Shareholders."
The Shares offered hereby may be sold by the Selling Shareholders
directly or through agents, underwriters or dealers as designated from time to
time or through a combination of such methods. The Company will receive none
of the proceeds from any sale of Shares by or for the account of the Selling
Shareholders. The Selling Shareholders and any broker-dealers that
participate with one or more of the Selling Shareholders in the distribution
of the Shares may be deemed to be underwriters and any commissions received or
profit realized by them in connected with the resale of the Shares might be
deemed to be underwriting discounts and commissions under the Securities Act
of 1933, as amended (the "Securities Act"). See "Selling Shareholders" and
"Plan of Distribution."
The Company has agreed to bear all expenses relating to this
registration, other than underwriting discounts and commissions. In addition,
the Company has agreed to indemnify the Selling Shareholders against certain
liabilities, including liabilities under the Securities Act. See "Selling
Shareholders" and "Plan of Distribution."
The Common Stock is quoted on the NASDAQ National Market under the symbol
"BJCT". On December 23, 1996, the closing bid price of the Common Stock as
reported by NASDAQ was $0.75.
_____________________
See "Risk Factors" in this Prospectus for a discussion of certain factors
that should be considered by prospective purchasers of the Common Stock.
_____________________
THESE SECURITIES HAVE NOT BEEN APPROVED OR DISAPPROVED BY THE SECURITIES
AND EXCHANGE COMMISSION OR ANY STATE SECURITIES COMMISSION NOR HAS THE
SECURITIES AND EXCHANGE COMMISSION OR ANY STATE SECURITIES COMMISSION
PASSED UPON THE ACCURACY OR ADEQUACY OF THIS PROSPECTUS. ANY REPRESENTATION
TO THE CONTRARY IS A CRIMINAL OFFENSE.
The Shares may be offered from time to time in negotiated transactions or
otherwise at market prices prevailing at the time of each sale, subject to the
right of the Selling Shareholders to reject any order in whole or in part.
The date of this Prospectus is _____________________, 1997.
<PAGE>
AVAILABLE INFORMATION
The Company has filed with the Securities and Exchange Commission (the
"Commission"), 450 Fifth Street N.W., Washington, D.C. 20549, a Registration
Statement on Form S-3 (the "Registration Statement") under the Securities Act,
and the rules and regulations promulgated thereunder, with respect to the
Shares offered pursuant to this Prospectus. This Prospectus, which is part of
the Registration Statement, does not contain all of the information set forth
in the Registration Statement and the exhibits thereto. Certain financial and
other information relating to the Company is contained in the documents
indicated below under "Incorporation of Certain Documents By Reference" which
are not presented herein or delivered herewith. For further information with
respect to the Company and the Shares, reference is made to the Registration
Statement and such exhibits, copies of which may be examined without charge
at, or obtained upon payment of prescribed fees from, the Public Reference
Section of the Commission at Room 1024, Judiciary Plaza, 450 Fifth Street,
N.W., Washington, D.C. 20549 and will also be available for inspection and
copying at the regional offices of the Commission located at 7 World Trade
Center, Suite 1300, New York, New York 10048 and at Citicorp Center, 500 W.
Madison Street, Suite 1400, Chicago, Illinois 60661-2511.
Statements contained in this Prospectus as to the contents of any
contract or other document which is filed as an exhibit to the Registration
Statement are not necessarily complete, and each such statement is qualified
in its entirety by reference to the full text of such contract or document.
The Company is subject to the informational requirements of the
Securities Exchange Act of 1934, as amended (the "Exchange Act"), and, in
accordance therewith, files reports, proxy statements and other information
with the Commission. Such reports, proxy statements and other information can
be inspected and copied at the locations described above. Copies of such
materials can be obtained by mail from the Public Reference Section of the
Commission at 450 Fifth Street, N.W., Washington, DC 20549, at prescribed
rates. In addition, the Common Stock is listed on the NASDAQ National Market.
Material filed by the Company can be inspected at the offices of the National
Association of Securities Dealers, Inc., 1735 K Street, N.W., Washington, D.C.
20006.
INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE
The following documents, which have been filed by the Company with the
Commission, are incorporated herein by reference:
1. The Company's Annual Report on Form 10-K for the year ended
March 31, 1996.
2. The Company's Quarterly Report on Form 10-Q for the quarter ended
June 30, 1996.
3. The Company's Quarterly Report on Form 10-Q/A for the quarter ended
June 30, 1996.
4. The Company's Quarterly Report on Form 10-Q for the quarter ended
September 30, 1996.
5. The Company's Current Report on Form 8-K dated June 26, 1996.
6. The Company's Current Report on Form 8-K/A dated June 26, 1996.
7. The Company's Current Report on Form 8-K dated December 11, 1996.
8. The description of the Company's Common Stock contained in the
Company's registration statement under Section 12 of the Exchange Act,
dated January 29, 1987, and any amendment or report updating such
description, including without limitation, Amendment No. 1 thereto
dated October 5, 1987, Amendment No. 2 thereto dated October 26, 1987,
Amendment No. 3 thereto dated December 23, 1987, Amendment No. 4
thereto dated January 27, 1988 and Amendment No. 5 thereto dated
February 9, 1988, the Company's Current Reports on Form 8-K dated
December 17, 1992, November 29, 1995 and December 14, 1995.
All reports and other documents subsequently filed by the Company
pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act, prior to
the filing of a post-effective amendment which indicates that all securities
offered hereby have been sold or which deregisters all securities then
remaining unsold, shall be deemed to be incorporated by reference in and to be
a part of this Prospectus from the date of filing of such reports and
documents.
Any statement contained in a document incorporated or deemed to be
incorporated by reference herein shall be deemed to be modified or superseded
for purposes of this Prospectus to the extent that a statement contained
herein or in the Registration Statement containing this Prospectus or in any
other subsequently filed document which also is or is deemed to be
incorporated by reference herein modifies or supersedes such statement. Any
statement so modified or superseded shall not be deemed, except as so modified
or superseded, to constitute a part of this Prospectus. The Company will
provide without charge to each person to whom this Prospectus is delivered,
upon the request of such person, a copy of any or all of the foregoing
documents referred to above which have been or may be incorporated herein by
reference, other than exhibits to such documents (unless such exhibits are
specifically incorporated by reference into the information that this
Prospectus incorporates). Requests for such documents should be directed to
the Secretary of the Company at 7620 SW Bridgeport Road, Portland, Oregon
97224 (telephone number: (503) 639-7221).
THE COMPANY
Bioject develops, manufactures and markets a jet injection system for
needle-free drug delivery. Using this technology for injections virtually
eliminates the associated risk of contaminated needlestick injuries and
resulting blood-borne pathogen transmission, a major concern throughout the
healthcare industry. The Company manufactures and markets a professional jet
injection system, the Biojector 2000, which allows healthcare professionals to
inject medications through the skin, both intramuscularly and subcutaneously,
without a needle. The Biojector 2000 system consists of two components: a
hand-held, reusable jet-injector; and a sterile, single-use disposable
syringe. The system is capable of delivering variable dose needle-free
injections up to 1 ml. Additionally, the Company is manufacturing a self-
injection system for delivery of Betaseron(r) to multiple sclerosis patients
pursuant to an agreement with Schering AG, Germany, signed June 26, 1996 and
the Company is also developing systems for Hoffmann-La Roche to use with their
products pursuant to an agreement signed January 10, 1995.
The Company was formed in December 1992 for the sole purpose of acquiring
all the capital stock of Bioject Medical Systems Ltd. in a stock-for-stock
exchange in order to establish a U.S. domestic corporation as the publicly
traded parent company for Bioject Inc. and Bioject Medical Systems Ltd. All
references to the Company herein are to Bioject Medical Technologies Inc. and
its subsidiaries, unless the context requires otherwise. The Company's
executive offices and operations are located at 7620 S.W. Bridgeport Road,
Portland, Oregon 97224, and its telephone number is (503) 639-7221.
The Company's operations are conducted by Bioject Inc., an Oregon
corporation, which is a wholly-owned subsidiary of Bioject Medical Systems
Ltd. Bioject Medical Systems Ltd., a company organized under the laws of
British Columbia, Canada, is, in turn, wholly-owned by the Company.
"Biojector(r)" and "Bioject(r)" are trademarks of the Company.
RECENT DEVELOPMENTS
In December 1996, announced that it will supply the Biojector 2000 to the
Department of Health for the City of New York for use in its Hepatitis B
vaccine program to be administered to students in the public middle school
system.
In December 1996, the Company completed a private placement (the
"Placement") of 3,120,000 units, each unit consisting of one share of Common
Stock and one warrant (a "Warrant") to purchase one share of Common Stock at
an exercise price of $1.00. The Warrants, which are exercisable in whole or
from time to time in part, expire five years from the date of issuance, and
are transferable subject to compliance with all applicable federal and state
securities laws. Proceeds to the Company, net of commissions (excluding
estimated expenses) was $2 million. Preferred Technology, Inc. ("PTI") acted
as agent in connection with the Placement and in connection therewith,
received $107,640 as a placement fee and a warrant to acquire 156,000 shares
of Common Stock at a exercise price per share of $0.828125 (the "Agent's
Warrant").
RISK FACTORS
The Shares offered hereby involve a high degree of risk. In addition to
the other information in this Prospectus, the following factors should be
considered carefully in evaluating the Company and its business before making
an investment in the Shares offered hereby. This Registration Statement and
documents incorporated herein contain forward-looking statement within the
meaning of Section 27A of the Securities Act. Discussion containing such
forward-looking statements may be found in the material within this
Registration Statement generally as well as within the documents listed under
"Incorporation of Certain Documents by Reference" and documents subsequently
filed pursuant to Section 13(a), 13(c) 14 and 15(d) of the Exchange Act.
Actual results could differ materially from those projected in the forward-
looking statements as a result of the risk factors set forth below and the
matters set forth in the Registration Statement generally. The Company
cautions the reader that this list of factors may not be exhaustive.
Uncertainty of Market Acceptance. The Company's success will depend upon
market acceptance of its jet injection drug delivery system, the Biojector
2000 system, and, to a lesser extent, other products under development.
Currently, the dominant technology used for intramuscular and subcutaneous
injections is the hollow-needle syringe. Needle-syringes, while low in cost,
have limitations, particularly relating to contaminated needlestick injuries.
Use of the Biojector 2000 system for intramuscular and subcutaneous injections
virtually eliminates the associated risk of these injuries; however, the cost
per injection is significantly higher. As with any new technology, there can
be no assurance that the Biojector 2000 system will compete successfully. A
previous jet injection system manufactured by the Company did not achieve
market acceptance and is no longer being marketed. The Biojector 2000 was
introduced in January 1993. To date, the major portion of sales have been to
HMI which have not been placed in service and which the Company has committed
to repurchase at a substantial discount to the original selling price. Failure
of the Biojector 2000 system to gain market acceptance would have a material
adverse effect on the Company's financial condition and results of operations.
History of Losses; Uncertain Profitability. Since its formation in 1985, the
Company has incurred significant annual operating losses and negative cash
flow. At September 30, 1996, the Company had an accumulated deficit of $32.3
million. The Company's revenues to date have been derived primarily from
licensing and technology fees, and from product sales, a majority of which were
sales to dealers for the stocking of inventories and to HMI. There can be no
assurance that the Company will be able to generate significant revenues or
achieve profitability.
Need for Additional Financing. The Company anticipates that the cash on hand
at December 15, 1996 combined with revenues and other cash receipts, will be
sufficient to meet the cash requirements of the Company's current operations
into the second quarter of fiscal 1998. Additional financing will be required
before that time to provide for working capital needs and cash reserves.
However, the Company may require additional capital sooner for a number of
reasons, including poor operating results, unanticipated expenses, growth
which is more rapid than anticipated, or new product development programs.
Failure to obtain needed additional capital on terms acceptable to the
Company, or at all, could significantly restrict the Company's operations and
ability to continue product development and growth and materially adversely
affect the Company's business.
Limited Manufacturing Experience; Need to Reduce Unit Cost. The Company has
limited experience manufacturing its products in commercial quantities. The
Company has increased its production capacity for the Biojector 2000 system
through automation of, and changes in, production methods. The current cost
per injection of the Biojector 2000 system is substantially higher than that
of traditional needle-syringes, its principal competition. A key element of
the Company's business strategy is to reduce the overall system cost through
automating production and packaging. The Company has experienced and may
experience setbacks and delays in its cost reduction efforts including failure
to deliver reduced cost parts to specifications. There can be no assurance
that the Company will be able to develop and implement effective high volume
production or achieve necessary unit cost reductions. Failure to do either
would adversely affect the Company's financial condition and results of
operations.
Governmental Regulation. The Company's products and manufacturing operations
are subject to extensive government regulation, both in the U.S. and abroad.
In the U.S., the development, manufacture, marketing and promotion of medical
devices are regulated by the Food and Drug Administration ("FDA") under the
Federal Food, Drug, and Cosmetic Act ("FFDCA"). In 1987, the Company received
clearance from the FDA under Section 510(k) of the FFDCA to market a hand-held
CO2-powered jet injection system. The FFDCA provides that new premarket
notifications under Section 510(k) of the FFDCA are required to be filed when,
among other things, there is a major change or modification in the intended
use of a device or a change or modification to a legally marketed device that
could significantly affect its safety or effectiveness. A device manufacturer
is expected to make the initial determination as to whether the change to its
device or its intended use is of a kind that would necessitate the filing of a
new 510(k) notification. Although the Biojector 2000 system incorporates
changes from the system with respect to which the Company's 1987 510(k)
marketing clearance was received and expands its intended use, the Company
made the determination that these were not major changes or modifications in
intended use or changes in the device that could significantly affect the
safety or effectiveness of the device and that, accordingly, the 1987 510(k)
clearance permitted the Company to market the Biojector 2000 system in the
U.S. In June 1994, the Company received clearance from the FDA under 510(k)
to market a version of its Biojector 2000 system in a configuration targeted
at high volume injection applications.
Future changes to manufacturing procedures could necessitate the filing of a
new 510(k) notification. Also, future products, product enhancements or
changes, or changes in product use may require clearance under Section 510(k),
or they may require FDA premarket approval ("PMA") or other regulatory
approvals. PMAs and these other regulatory approvals generally involve more
extensive prefiling testing than a 510(k) clearance and a longer FDA review
process. Under current FDA policy, applications involving prefilled syringes
would be evaluated by the FDA as drugs rather than devices, requiring NDAs or
ANDAs. Depending on the circumstances, drug regulation can be more
bureaucratic and time consuming than devise regulation.
FDA regulatory processes are time consuming and expensive, and there can be no
assurance that product applications submitted by the Company will be cleared
or approved by the FDA. In addition, the Company's products must be
manufactured in compliance with Good Manufacturing Practices ("GMP") specified
in regulations under the FDA Act. The FDA has broad discretion in enforcing
the FDA Act, and noncompliance with the Act could result in a variety of
regulatory actions ranging from product detentions, device alerts or field
corrections, to mandatory recalls, seizures, injunctive actions, and civil or
criminal penalties.
Distribution of the Company's products in countries other than the U.S. may be
subject to regulation in those countries. An application was made to the
Japan Ministry of Health and Welfare to obtain necessary approvals to market
the Biojector 2000 system in Japan which was not carried to completion by the
Company's then Japanese distributor. The Company cannot accurately predict
the time required for any such regulatory approval to be obtained. There can
be no assurance that approval will be granted for any particular regulatory
application or that approval will be granted to the extent of the scope
claimed in any such application. Regulatory authorities may request
additional clinical data or other documentation to support regulatory
applications by the Company. Any such request could significantly delay
approval based on the time and effort required by the Company to obtain the
required additional information. In addition, the costs associated with
obtaining additional clinical data could have a material adverse effect on the
Company's results of operations, if pursued.
Uncertainty in Healthcare Industry; Government Healthcare Reform Proposal.
The healthcare industry is subject to changing political, economic and
regulatory influences that may affect the procurement practices and operations
of healthcare facilities. During the past several years, the healthcare
industry has been subject to increased government regulation of reimbursement
rates and capital expenditures. Among other things, third party payors are
increasingly attempting to contain healthcare costs by limiting both coverage
and reimbursement levels for healthcare products and procedures. Because the
price of the Biojector 2000 system exceeds the price of needle injection
systems, cost control policies of third party payors, including government
agencies, may adversely affect use of the Biojector 2000 system.
Dependence on Third-Party Relationships. The Company is dependent on third
parties for distribution of the Biojector 2000 system to certain market
segments, for the manufacture of component parts, and for assistance with the
development and distribution of its future Betaseron self-injection and
application specific systems.
The Company intends to seek relationships to distribute to the physician
office market in the future. Past dealer relationships have not been
successful. There can be no assurance that the Company's future dealers will
provide sufficient sales support to establish the Company's current product.
The Company's current manufacturing processes for the Biojector 2000 jet
injector and disposable syringes consist primarily of assembly of component
parts supplied by outside suppliers. Certain of these components are
currently obtained from single sources, with some components requiring
significant production lead times. In the past, the Company has experienced
delays in the delivery of certain components, although to date no such delays
have had a material adverse effect on the Company's operations. There can be
no assurance that the Company will not experience delays in the future, or
that such delays would not have a material adverse effect on the Company's
financial condition and result of operations.
The Company has entered into agreements with certain major pharmaceutical
companies for development and distribution of jet injection systems. These
companies have the right to terminate these agreements at certain phases as
defined in the agreements. There can be no assurance these companies'
interest and participation in the projects will continue. Failure to receive
additional funding from these companies could adversely affect the development
and production of the products involved and, correspondingly, the Company's
financial condition and results of operations.
Ability to Manage Growth. If the Company's products achieve market
acceptance, the Company may experience rapid growth. Such growth may require
expanded customer services and support, increased personnel throughout the
Company, expanded operational and financial systems, and the implementation of
new control procedures. There can be no assurance that the Company will be
able to attract qualified personnel or successfully manage expanded
operations. As the Company expands, it may from time to time experience
constraints that would adversely affect its ability to satisfy customer demand
in a timely fashion. Failure to manage growth effectively could adversely
affect the Company's financial condition and results of operations.
Competition. The medical equipment market is highly competitive and
competition is likely to intensify. The Company's products compete primarily
with traditional needle-syringes, "safety syringes" and also with other
alternative drug delivery systems. While the Company believes its products
provide a superior drug delivery method, there can be no assurance that the
Company will be able to compete successfully with existing drug delivery
products. Many of the Company's competitors have longer operating histories
as well as substantially greater financial, technical, marketing and customer
support resources than the Company. There can be no assurance that one or
more of these competitors will not develop an alternative drug delivery system
that competes more directly with the Company's products, or that the Company's
products would be able to compete successfully with such a product.
Dependence on Single Technology. The Company's strategy has been to focus its
development and marketing efforts on its jet injection technology. This focus
renders the Company particularly sensitive to competing products and
alternative drug delivery systems. The Company believes that healthcare
providers' desire to minimize the use of the traditional needle-syringe has
stimulated development of a variety of alternative drug delivery systems such
as "safety syringes," jet injection systems and transdermal diffusion
"patches." In addition, pharmaceutical companies frequently attempt to
develop drugs for oral delivery instead of injection. While the Company
believes that for the foreseeable future there will continue to be a
significant need for injections, there can be no assurance that alternative
drug delivery methods will not be developed which are preferable to injection.
Patents and Proprietary Rights. The Company relies on a combination of trade
secrets, confidentiality agreements and procedures, and patent prosecution to
protect its proprietary technologies. The Company has been granted seven
patents in the United States and eight patents in certain other countries
covering certain technology embodied in its current jet injection system and
certain manufacturing processes. Additional patent applications are pending
in the U.S. and certain foreign countries. There can be no assurance that the
claims contained in any patent application will be allowed, or that any patent
will provide adequate protection for the Company's products and technology.
In the absence of patent protection, the Company may be vulnerable to
competitors who attempt to copy the Company's products or gain access to its
trade secrets and know-how. In addition, the laws of foreign countries may
not protect the Company's proprietary rights to this technology to the same
extent as the laws of the U.S. The Company believes that it has independently
developed its technology and attempts to ensure that its products do not
infringe the proprietary rights of others, and the Company knows of no
infringement claims. However, any such claims could have a material adverse
affect on the Company's financial condition and results of operations.
Product Liability and Reliability. Producers of medical devices may face
substantial liability for damages in the event of product failure or if it is
alleged the product caused harm. The Company currently maintains product
liability insurance and has not experienced any product liability claims to
date. There can be no assurance, however, that the Company will not be
subject to such claims, that the Company's current insurance would cover such
claims, or that adequate insurance will continue to be available on acceptable
terms to the Company in the future. The Company's business could be adversely
affected by product liability claims.
Dependence upon Key Employees. The Company's success is dependent upon the
retention of its executive officers and other key employees. Competition
exists for qualified personnel and the Company's success will depend in part
upon attracting and retaining such personnel. Failure in these efforts could
have a material adverse effect on the Company's business, financial condition
or results of operations.
Shares Eligible For Future Sale. Of the 18,736,712 shares of common stock
currently outstanding, 1,500,000 of those shares were held in escrow for WAM
Partnership, a limited partnership of which Mr. Carl Wilcox is the managing
partner. In June 1996, the shares were released from escrow and may be sold.
In November and December 1995, the Company completed a private placement of
2,303,009 units (each unit representing one share of common stock and a
warrant to purchase one share of common stock). The Company also granted a
warrant to its placement agent in the private placement to purchase 137,086
shares of common stock. The shares issued in the private placement were
registered for resale on a Registration Statement on Form S-3. In December
1996, the Company completed the Private Placement of 3,120,000 units (each
unit representing one share of common stock and a warrant to purchase one
share of common stock). The Company also granted a warrant to its placement
agent in the private placement to purchase 156,000 shares of common stock.
See "Recent Developments." In each of the private placements, the Company
also granted registration rights with respect to the shares issuable upon
exercise of the warrants. Sales of substantial numbers of common stock in the
public market, or the availability of such shares for sale, could adversely
affect the market price for the common stock and make it more difficult for
the Company to raise funds through equity offerings in the future.
Possible Adverse Effects on Trading Market. The Common Stock is quoted on the
NASDAQ National Market. There are a number of continuing requirements that
must be met in order for the Common Stock offered hereby to remain eligible
for quotation on the NASDAQ National Market or the NASDAQ SmallCap Market. In
order to continue to be quoted on NASDAQ, a company must maintain $2 million
in total assets, a $200,000 market value of the public float and $1 million in
total capital and surplus. In addition, continued quotation requires two
marketmakers and a minimum bid price of $1.00 per share; provided, however,
that if a company falls below such a minimum bid, it will remain eligible for
continued quotation on NASDAQ if the market value of the public float is at
least $1 million and the company has $2 million in capital and surplus. In
November 1996, NASDAQ approved changes to its quantitative and qualitative
standards for issuers listing on NASDAQ, subject to public comment and
approval by the Commission. Among the proposed changes are the elimination of
the alternative test for issuers failing to meet the minimum bid price of
$1.00 and an increase in the quantitative standards for both the NASDAQ
National Market and the NASDAQ SmallCap Market.
The failure to meet the maintenance criteria in the future could result in the
delisting of the Company's Common Stock from NASDAQ. In such event, trading,
if any, in the Common Stock may then continue to be conducted in the non-
NASDAQ over-the-counter market. As a result, an investor may find it more
difficult to dispose of, or to obtain accurate quotations as to the market
value of, the Company's Common Stock. In addition, if the Common Stock was
delisted from trading on NASDAQ and the trading price of the Common Stock was
less than $5.00 per share, trading in the Common Stock would also be subject
to the requirements of certain rules promulgated under the Exchange Act, which
require additional disclosure by broker-dealers in connection with any trades
involving a stock defined as a penny stock. The additional burdens imposed
upon broker-dealers may discourage broker-dealers from effecting transactions
in penny stocks, which could reduce the liquidity of the shares of Common
Stock and thereby have a material adverse effect on the trading market for the
securities.
Possible Volatility of Stock Price. The market for the Company's Common Stock
and for the securities of other early stage, small market-capitalization
companies has been highly volatile in recent years. The Company believes that
factors such as quarter-to-quarter fluctuations in financial results, new
product introductions by the Company or its competition, public announcements,
changing regulatory environments, sales of Common Stock by certain existing
shareholders and substantial product orders could contribute to the volatility
of the price of the Company's Common Stock, causing it to fluctuate
dramatically. General economic trends such as recessionary cycles and
changing interest rates may also adversely affect the market price of the
Company's Common Stock.
USE OF PROCEEDS
The Shares offered hereby are being registered for the account of the
Selling Shareholders and, accordingly, the Company will not receive any of the
proceeds from the sale of the Shares.
SELLING SHAREHOLDERS
The Shares being offered for resale by the Selling Shareholders were
acquired in connection with the Placement and include (i) the Common Stock
sold thereunder and (ii) the Common Stock issuable upon exercise of the
Warrants and the Agent's Warrant. The term "Selling Shareholder" includes all
persons acquiring securities in the Placement and persons acquiring such
securities in permitted transfers from original holders thereof pursuant to
the Registration Rights Agreement (described below) in transactions not
requiring registration under the Securities Act.
In connection with the Placement, the Company and the purchasers entered
into a Registration Rights Agreement pursuant to which the Company agreed to
use its best efforts to keep the registration, of which this Prospectus is a
part, effective for at lease two years from the date hereof. In addition, the
Company granted the Selling Shareholders certain "piggyback" registration
rights in connection with the registration under the Securities Act of
securities in connection with a public offering (other than a registration
relating to the sale of securities solely to participants in employee benefit
plans or in connection with certain transactions requiring shareholder
approval). All rights granted pursuant to the Registration Rights Agreement
terminate on the earlier of December 9, 2001 or such time as the aggregate
number of Shares held by the Selling Shareholders represents less than 1% of
the outstanding shares of the Company's Common Stock.
The following table sets forth certain information regarding the
beneficial ownership of shares of Common Stock by the Selling Shareholders as
of December 11, 1996, and as adjusted to reflect the sale of the Shares.
<TABLE>
<CAPTION>
Number of Shares Maximum Number of Shares Owned After
Owned Shares to be Sold Offering(1)
Prior To under this --------------------
Name Offering Prospectus Number Percent
- ----------------------------- ---------------- ----------------- ---------- -------
<S> <C> <C> <C> <C>
Hambrecht & Quist(2) 3,383,400 2,380,000 1,003,400 5.0%
Paramount Capital(3) 2,857,142 2,857,142 -- *
Porter Capital Partners L.P.(4) 1,250,000 400,000 850,000 4.4%
Julie T. and Robert A.
Berlacher(5) 389,356 200,000 189,356 *
Robert A. Berlacher(6) 147,500 60,000 87,500 *
Franz J. Berlacher(7) 260,000 100,000 160,000 *
Harry Mittelman(8) 113,846 40,000 73,846 *
Sarlo Family Supporting
Foundation(9) 42,858 42,858 -- *
MDNH Partners(10) 100,000 100,000 -- *
James A. Magdlen(11) 93,250 60,000 33,250 *
Preferred Technology, Inc.(12) 45,000 45,000 -- *
Thomas Ashton (13) 30,000 30,000 -- *
Frank Gauvain (14) 5,000 5,000 -- *
Edward Elliott (15) 28,000 28,000 -- *
Frank Lyles (16) 28,000 28,000 -- *
Sands Brothers & Co., Ltd. 20,000 20,000 -- *
---------------- ----------------- ---------- -------
TOTAL 8,793,352 6,396,000 2,397,352
================ ================= ==========
_________________
* Less than 1%.
(1) Assumes that all of the Selling Shareholders will sell all Shares during the effective
period.
(2) Includes (i) 1,200,500 shares of Common Stock and (ii) 654,500 shares of Common Stock
issuable upon exercise of the Warrants, held in the name of H&Q Healthcare Investors. Also
includes (i) 992,900 shares of Common Stock and (ii) 535,500 shares of Common Stock issuable upon
exercise of the Warrants, held in the name of H&Q Life Sciences Investors.
(3) Includes (i) 1,000,000 shares of Common Stock and (ii) 1,000,000 shares of Common Stock
issuable upon exercise of the Warrants, held in the name of The Aries Trust. Also includes (i)
428,571 shares of Common Stock and (ii) 428,571 shares of Common Stock issuable upon exercise of
the Warrants, held in the name of Aries Domestic Fund L.P.
(4) Includes 200,000 shares of Common Stock issuable upon exercise of the Warrants. Also
includes (i) 425,000 shares of Common Stock and (ii) 425,000 shares of Common Stock issuable upon
exercise of the warrants, held in the name of Porter Partners, L.P.
(5) Includes (i) 100,000 shares of Common Stock and (ii) 100,000 shares of Common Stock
issuable upon exercise of the Warrants held in the name of Robert A. Berlacher and Julie T.
Berlacher, JTROS. Also includes 9,350 shares of Common Stock issuable upon exercise of warrants
held in the name Robert A. Berlacher. Also includes (i) 6,667, 6,667, 6,667, 6,667, 6,667 and
6,667 shares of Common Stock and (ii) 6,667, 6,667, 6,667, 6,667, 6,667 and 6,667 shares of
Common Stock issuable upon exercise of warrants, held by Julie T. Berlacher as trustee, for the
benefit of minor children, Elizabeth A. Berlacher, Kristen M. Berlacher, Robert T. Berlacher,
Kelsey L. Berlacher, Lydia J. Berlacher and Heidi O. Berlacher, respectively. Julie Berlacher is
the beneficial owner of the shares held for the benefit of her children. Also includes 66,667
shares of Common Stock issuable upon exercise of warrants held in the Julie T. Berlacher Trust,
of which Julie Berlacher is the trustee. Also includes 33,335 shares of Common Stock issuable
upon exercise of warrants held by Julie T. Berlacher. Robert A. Berlacher and Julie T. Berlacher
are husband and wife.
(6) Includes (i) 67,500 shares of Common Stock, (ii) 30,000 shares of Common Stock issuable
upon exercise of the Warrants and (iii) 50,000 shares of Common Stock issuable upon exercise of
warrants, held in the name of Paine Webber as IRA Custodian FBO/Robert A. Berlacher.
(7) Includes (i) 80,000 shares of Common Stock, (ii) 50,000 shares of Common Stock issuable
upon exercise of the Warrants and (iii) 30,000 shares of Common Stock issuable upon exercise of
warrants, held in the name of Berlacher Cardiology Associates: Profit Sharing Plan and Trust FBO
Franz J. Berlacher. Also includes (i) 50,000 shares of Common Stock and (ii) 50,000 shares of
Common Stock issuable upon exercise of warrants, held in the name of Audrey E. Berlacher. Audrey
E. Berlacher is the wife of Franz A. Berlacher.
(8) Includes (i) 20,000 shares of Common Stock and (ii) 20,000 shares of Common Stock
issuable upon exercise of the Warrants, held in the name of Harry Mittelman, MD Pension Profit
Sharing Plan. Also includes 36,923 shares of Common Stock issuable upon exercise of warrants.
(9) Includes (i) 21,429 shares of Common Stock and (ii) 21,429 shares of Common Stock
issuable upon exercise of the Warrants, held in the name of Sarlo Family Supporting Foundation.
Mr. Carlo Cannell is the trustee of the foundation.
(10) Includes 50,000 shares of Common Stock issuable upon exercise of the Warrants. Mike
Engmann is a partner in MDNH Partners.
(11) Includes 30,000 shares of Common Stock issuable upon exercise of the Warrants. Also
includes 33,250 shares of Common Stock, 20,250 of which are held in the name of James & Barbara
Magdlen Living Trust.
(12) Includes 45,000 shares of Common Stock issuable upon exercise of the Agent's Warrant.
Preferred Technology, Inc. acted as placement agent in the Placement.
(13) Includes 30,000 shares issuable upon exercise of the Agent's Warrant.
(14) Includes 5,000 shares issuable upon exercise of the Agent's Warrant.
(15) Includes 28,000 shares issuable upon exercise of the Agent's Warrant.
(16) Includes 28,000 shares issuable upon exercise of the Agent's Warrant.
(17) Includes 20,000 shares issuable upon exercise of the Agent's Warrant.
</TABLE>
No Selling Shareholder has held any position or office, or other material
relationship with the Company or any of its predecessors or affiliates within
the past three years. Robert A. Berlacher is an employee, principal and
shareholder of Pacific Growth Equities, Inc. ("Pacific Growth"). Pacific
Growth acted as the managing underwriter of a public offering of the Company's
Common Stock in 1993, and as agent to the Company in a private placement in
November and December 1995. Pacific Growth currently makes a market in the
Common Stock. Mike Engmann is an officer of PTI. Thomas Ashton, Frank
Gauvain, Edward Elliott and Frank Lyles are employees, principals and
shareholders of PTI. PTI acted as agent to the Company in the Placement.
See "Recent Developments."
PLAN OF DISTRIBUTION
The distribution of the Shares by the Selling Shareholders may be
effected from time to time in one or more transactions (which may involve
block transactions), in special offerings, exchange distributions and/or
secondary distributions, in negotiated transactions, or a combination or such
methods of sale, at market prices prevailing at the time of sale, at prices
related to such prevailing market prices or at negotiated prices. Such
transactions may be effected on a stock exchange or the over-the-counter
market. The Selling Shareholders may effect such transactions by selling the
Shares to or through broker-dealers, and such broker-dealers may receive
compensation in the form of underwriting discounts, concessions or commissions
from one or more of the Selling Shareholders for whom they may act as agent
(which compensation may be in excess of customary commissions). Without
limiting the foregoing, such brokers may act as dealers by purchasing any and
all of the Shares covered by this Prospectus either as agents for others or as
principals for their own accounts and reselling such securities pursuant to
this Prospectus. The Selling Shareholders and any broker-dealers or other
persons acting on the behalf that participate with such Selling Shareholders
in the distribution of the Shares may be deemed to be underwriters and any
commissions received or profit realized by them on the resale of the Shares
may be deemed to be underwriting discounts and commissions under the
Securities Act. As of the date of this Prospectus, the Company is not aware
of any agreement, arrangement or understanding between any broker or dealer
and any of the Selling Shareholders with respect to the offer or sale of the
Shares pursuant to this Prospectus.
At the time that any particular offering of Shares is made, to the extent
required by the Securities Act, a prospectus supplement will be distributed,
setting forth the terms of the offering, including the aggregate number of
Shares being offered, the names of any underwriters, dealers or agents, any
discounts, commissions and other items constituting compensation from the
Selling Shareholders and any discounts, commissions or concessions allowed or
reallowed or paid to dealers.
The Selling Shareholders may from time to time pledge the Shares owned by
them to secure margin or other loans made to one or more of the Selling
Shareholders. Thus, the person or entity receiving the pledge of any of the
Shares may sell them, in a foreclosure sale or otherwise, in the same manner
as described above for a Selling Shareholder.
The Company will not receive any of the proceeds from any sale of the
Shares by the Selling Shareholders offered hereby.
Pursuant to the Registration Rights Agreement, the Company has agreed to
indemnify the Selling Shareholders against certain liabilities, including
liabilities under the Securities Act. The Company shall bear customary
expenses incident to the registration of the Shares for the benefit of the
Selling Shareholders in accordance with the Registration Rights Agreement,
other than underwriting discounts and commissions directly attributable to the
sale of such securities by or on behalf of the Selling Shareholders.
The Company has agreed to use its best efforts to keep the Registration
Statement of which this Prospectus is a part effective for at least two years
from December 11, 1996.
LEGAL MATTERS
The validity of the issuance of the shares of Common Stock offered hereby
will be passed upon for the Company by Bogle & Gates P.L.L.C., Seattle,
Washington.
EXPERTS
The consolidated financial statements and schedule incorporated by
reference in this Prospectus and elsewhere in the Registration Statement have
been audited by Arthur Andersen LLP, independent public accountants, as
indicated in their reports with respect thereto, and are incorporated by
reference herein in reliance upon the authority of said firm as experts in
accounting and auditing in giving said reports.
Future financial statements of the Company and the reports thereon of
Arthur Andersen LLP also will be incorporated by reference in this Prospectus
in reliance upon the authority of that firm as experts in accounting and
auditing in giving those reports to the extent said firm has audited those
financial statements and consented to the use of their reports thereon.
<PAGE>
=============================================================================
No dealer, salesperson, or any other person has been authorized to give
any information or to make any representations other than those contained in
this Prospectus in connection contained herein, and, if given or made, such
information or representations must not be relied upon as having been
authorized by the Company. This Prospectus does not constitute an offer of
any securities other than those to which it relates or an offer to sell, or a
solicitation of an offer to buy, those to which it relates in any jurisdiction
where, or to any person to whom, it is unlawful to make such an offer. The
delivery of this Prospectus at any time does not imply that there has been no
change in the information set forth herein or in the affairs of the Company
since the date hereof.
6,396,000 Shares
Common Stock
(without par value)
________________________
BIOJECT MEDICAL TECHNOLOGIES INC.
________________
PROSPECTUS
________________
TABLE OF CONTENTS
________________________
Available Information
Incorporation of Certain Documents by Reference
The Company
Recent Developments
Risk Factors
Use Of Proceeds
Selling Shareholders
Plan of Distribution
Legal Matters
Experts
________________________, 1997
=============================================================================
<PAGE>
PART II
INFORMATION NOT REQUIRED IN PROSPECTUS
ITEM 14. OTHER EXPENSES OF ISSUANCE AND DISTRIBUTION.
The following table itemizes the expenses incurred by the Company in
connection with the shares of Common Stock being registered. All of the
amounts shown are estimates except the Securities and Exchange registration
fee.
Item Amount
---- ------
Securities and Exchange Commission
Registration Fee........................ $1,545.00
Blue Sky Fees and Expenses................ *
Accounting Fees and Expenses.............. *
Legal Fees and Expenses................... *
Miscellaneous............................. *
--------
TOTAL......................... $ *
=========
_____________
* To be completed by amendment.
The Selling Shareholders will pay no portion of the foregoing expenses.
ITEM 15. INDEMNIFICATION OF DIRECTORS AND OFFICERS.
Generally, Sections 60.387 through 60.414 of the Oregon Business
Corporation Act (the "Act") authorize a court to award, or a corporation's
board of directors to grant, indemnification to directors and officers in
circumstances where the officer or director acted in good faith, in a manner
that the director or officer reasonably believed to be in (or at least not
opposed to) the best interests of the corporation and, if in a criminal
proceeding, if the director or officer had no reasonable cause to believe his
conduct was unlawful. Article IX of the Company's Bylaws provides for
indemnification to the greatest extent permitted by the Oregon Act.
Section 60.047 of the Oregon Act authorizes a corporation to limit a
director's liability to the corporation or its shareholders for monetary
damages resulting from conduct as a director, except in certain circumstances
involving breach of the director's duty of loyalty to the corporation or its
shareholders, intentional misconduct or knowing violation of the law, self
dealing or approval of illegal corporate loans or distributions, or any
transaction from which the director personally receives a benefit in money,
property or services to which the director is not legally entitled. Article
VII of the Company's Articles of Incorporation contains provisions
implementing, to the fullest extent allowed, limitations on a director's
liability to the Company or its shareholders. The Company currently maintains
officers' and directors' liability insurance.
(a) EXHIBITS.
Exhibit
Number Description
- ------- -----------
4.1 Form of Registration Rights Agreement (Incorporated by reference
to Exhibit 4.8 of the Registrant's Current Report on Form 8-K
dated December 11, 1996)
4.2 Form of Stock Subscription Agreement (Incorporated by reference
to Exhibit 4.5 of the Registrant's Current Report on Form 8-K
dated December 11, 1996)
4.3 Form of Series D Common Stock Purchase Warrant (Incorporated by
reference to Exhibit 4.6 of the Registrant's Current Report on
Form 8-K dated December 11, 1996)
4.4 Form of Series E Common Stock Purchase Warrant (Incorporated by
reference to Exhibit 4.7 of the Registrant's Current Report on
Form 8-K dated December 11, 1996)
5.1 Opinion of Bogle & Gates P.L.L.C.
23.1 Consent of Bogle & Gates P.L.L.C. (included in Exhibit 5.1)
23.2 Consent of Arthur Andersen LLP
24.1 Power of Attorney (see signature page)
ITEM 17 UNDERTAKINGS.
(a) Rule 415 Offering.
The undersigned Registrant hereby undertakes:
(1) To file, during any period in which offers or sales are
being made, a post-effective amendment to this Registration Statement;
(i) To include any prospectus required by Section
10(a)(3) of the Securities Act of 1933;
(ii) To reflect in the prospectus any facts or events
arising after the effective date of this Registration Statement (or the most
recent post-effective amendment thereof), which, individually or in the
aggregate, represent a fundamental change in the information set forth in this
Registration Statement. Notwithstanding the foregoing, any increase or
decrease in volume of securities offered (if the total dollar value of
securities offered would not exceed that which was registered) and any
deviation from the low or high and of the estimated maximum offering range may
be reflected in the form of prospectus filed with the Commission pursuant to
Rule 424(b) if, in the aggregate, the changes in volume and price represent no
more than 20 percent change in the maximum aggregate offering price set forth
in the "Calculation of Registration Fee" table in the effective registration
statement.
(iii) To include any material information with respect
to the plan of distribution not previously disclosed in this Registration
Statement or any material change to such information in this Registration
Statement;
provided, however, that the undertakings set forth in paragraphs (a)(1)(i) and
(a)(1)(ii) above do not apply if this Registration Statement is on Form S-3,
Form S-8 or Form F-3, and the information required to be included in a post-
effective amendment by those paragraphs is contained in periodic reports filed
by the Registrant pursuant to Section 13 or Section 15(d) of the Securities
Exchange Act of 1934 that are incorporated by reference in this Registration
Statement.
(2) That, for the purpose of determining any liability under
the Securities Act of 1933, each such post-effective amendment shall be deemed
to be a new registration statement relating to the securities offered therein,
and the offering of such securities as that time shall be deemed to be the
initial bona fide offering thereof;
(3) To remove from registration by means of post-effective
amendment any of the securities being registered which remain unsold at the
termination of the offering.
(b) Filings Incorporating Subsequent Exchange Act Documents by
Reference.
The undersigned Registrant hereby undertakes that, for the
purposes of determining any liability under the Securities Act of 1933, each
filing of the Registrant's annual report pursuant to Section 13(a) or Section
15(d) of the Securities Exchange Act of 1934 (and, where applicable, each
filing of an employee benefit plan's annual report pursuant to Section 15(d)
of the Securities Exchange Act of 1934) that is incorporated by reference in
the Registration Statement shall be deemed to be a new registration statement
relating to the securities offered therein and the offering of such securities
at that time shall be deemed to be the initial bona fide offering thereof.
(h) Indemnification for Liabilities.
Insofar as indemnification for liabilities arising under the
Securities Act of 1933 may be permitted to directors, officers and controlling
persons of the Registrant pursuant to the provisions described in Item 15
above, or otherwise, the Registrant has been advised that in the opinion of
the Securities and Exchange Commission such indemnification is against public
policy as expressed in the Securities Act of 1933 and is, therefore,
unenforceable. In the event that a claim for indemnification against such
liabilities (other than the payment by the Registrant of expense incurred or
paid by a director, officer or controlling person of the Registrant in the
successful defense of any action, suit or proceeding) is asserted by such
director, officer or controlling person in connection with the securities
being registered, the Registrant will, unless in the opinion of its counsel
the matter has been settled by controlling precedent, submit to a court of
appropriate jurisdiction the question whether such indemnification by it is
against public policy as expressed in the Securities Act of 1933 and will be
governed by the final adjudication of such issue.
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, the
Registrant certifies that it has reasonable grounds to believe that it meets
all the requirements for filing on Form S-3 and has duly caused this
Registration Statement to be signed on its behalf by the undersigned,
thereunto duly authorized, in the City of Portland, State of Oregon, on
December 27, 1996.
BIOJECT MEDICAL TECHNOLOGIES INC.
BY: /s/ James C. O'Shea
--------------------------------
James C. O'Shea
Chairman, Chief Executive Officer
and President
POWER OF ATTORNEY
Each person whose signature appears below constitutes and appoints James
C. O'Shea and Peggy J. Miller, or either of them, his/her attorneys-in-fact,
with the power of substitution, for him/her in any and all capacities, to sign
any amendments to this Registration Statement, and to file the same, with
exhibits thereto and other documents in connection therewith, with the
Securities and Exchange Commission, hereby ratifying and confirming all that
each of said attorneys-in-fact, or their substitute or substitutes, may do or
cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Act of 1933, this
Registration Statement has been signed by the following persons in the
capacities and on the dates indicated.
Signature Title Date
- --------- ----- ----
/s/ James C. O'Shea Chairman of the Board, Chief December 27, 1996
- ------------------- Executive Officer and President
James C. O'Shea (Principal Executive Officer)
/s/ Peggy J. Miller Vice President, Chief Financial December 27, 1996
- ------------------- Officer and Secretary/Treasurer
Peggy J. Miller (Principal Accounting and
Financial Officer)
/s/ William A. Gouveia Director December 27, 1996
- ----------------------
William A. Gouveia
/s/ John Ruedy, M.D. Director December 27, 1996
- --------------------
John Ruedy, M.D.
/s/ Cecil E. Spearman Director December 27, 1996
- ---------------------
/s/ Grace Keeney Fey Director December 27, 1996
- ---------------------
Grace Keeney Fey
/s/ Eric T. Herfindal Director December 27, 1996
- ---------------------
Eric T. Herfindal
<PAGE>
INDEX TO EXHIBITS
ACCOMPANYING THIS FILING
Exhibit
Number Description
- ------- -----------
5.1 Opinion of Bogle & Gates P.L.L.C.
23.2 Consent of Arthur Andersen L.L.P.
[BOGLE & GATES P.L.L.C. LETTERHEAD]
EXHIBIT 5.1
December 27, 1996
Bioject Medical Technologies Inc.
7620 S.W. Bridgeport Road
Portland OR 97224
Gentlemen and Ladies:
We are delivering this opinion in connection with the Registration
Statement on Form S-3 (the "Registration Statement") of Bioject Medical
Technologies Inc. (the "Company") to be filed with the Securities and Exchange
Commission under the Securities Act of 1933, as amended (the "Securities
Act"), with respect to an aggregate of 6,396,000 shares, without par value, of
common stock of the Company (the "Shares") to be resold by certain selling
shareholders named therein (the "Selling Shareholders").
We have examined and are familiar with originals or copies,
certified or otherwise identified to our satisfaction, of such documents,
corporate records and other instruments relating to the incorporation of the
Company and to the authorization and issuance of the Shares, and have made
such investigations of law, as we have deemed necessary and advisable.
Based upon the foregoing and having due regard for such legal
questions as we have deemed relevant, we are of the opinion that:
The 3,120,000 Shares, which were purchased by the Selling
Shareholders, have been duly authorized, and, when issued,
constituted or will constitute duly authorized, legally issued,
fully paid and nonassessable shares of common stock of the Company.
The 3,276,000 Shares, which will be issued to the Selling
Shareholders upon the exercise of warrants, have been duly
authorized, and, upon issuance and receipt of payment therefore
in accordance with the terms of the warrants, will constitute duly
authorized, legally issued, fully paid an nonassessable shares of
common stock of the Company.
We hereby consent to the filing of this opinion as an exhibit to
the Registration Statement referred to above, and to the reference to our firm
in the Prospectus constituting a part of the Registration Statement.
Very truly yours,
BOGLE & GATES P.L.L.C.
/s/ Bogle & Gates P.L.L.C.
Exhibit 23.2
CONSENT OF INDEPENDENT PUBLIC ACCOUNTANTS
As independent public accountants, we hereby consent to the incorporation by
reference in this Form S-3 Registration Statement and related Prospectus of
our report dated May 2, 1996 included in the Bioject Medical Technologies Inc.
Annual Report on Form 10-K for the fiscal year ended March 31, 1996 and to
all references to our firm included in this Registration Statement and related
Prospectus.
/s/ Arthur Andersen L.L.P.
Portland, Oregon,
December 23, 1996
